Ex vivo expanded mesenchymal stromal cell minimal quality requirements for clinical application

Maria Luisa Torre, Enrico Lucarelli, Simona Guidi, Maura Ferrari, Giulio Alessandri, Laura De Girolamo, Augusto Pessina, Ivana Ferrero

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Mesenchymal stromal cells (MSCs), as advanced therapy products, must satisfy all the requirements for human use of medicinal products, aiming to maintain the quality and safety of the cells. The MSC manufacturing process for clinical use should comply with the principles of Good Manufacturing Practice (GMP). This ensures that cell preparations are produced and controlled, from the collection and manipulation of raw materials, through the processing of intermediate products, to the quality controls, storage, labeling and packaging, and release. The objective of this document is to provide the minimal quality requirements for the MSC production and its delivery for clinical use, so that the safety of the final cell therapy product will not be compromised. For this purpose, the document evaluates the most important steps of GMP-compliant MSC production: the isolation and expansion process; the validation phase of the process, including all quality controls for the characterization, functionality, potency, and safety of MSCs; and the quality control at the batch release to guarantee the safety of patient infusion.

Original languageEnglish
Pages (from-to)677-685
Number of pages9
JournalStem Cells and Development
Volume24
Issue number6
DOIs
Publication statusPublished - Mar 15 2015

Fingerprint

Mesenchymal Stromal Cells
Quality Control
Safety
Cell Separation
Product Packaging
Patient Safety
Cell- and Tissue-Based Therapy
Therapeutics

ASJC Scopus subject areas

  • Cell Biology
  • Developmental Biology
  • Hematology
  • Medicine(all)

Cite this

Ex vivo expanded mesenchymal stromal cell minimal quality requirements for clinical application. / Torre, Maria Luisa; Lucarelli, Enrico; Guidi, Simona; Ferrari, Maura; Alessandri, Giulio; De Girolamo, Laura; Pessina, Augusto; Ferrero, Ivana.

In: Stem Cells and Development, Vol. 24, No. 6, 15.03.2015, p. 677-685.

Research output: Contribution to journalArticle

Torre, Maria Luisa ; Lucarelli, Enrico ; Guidi, Simona ; Ferrari, Maura ; Alessandri, Giulio ; De Girolamo, Laura ; Pessina, Augusto ; Ferrero, Ivana. / Ex vivo expanded mesenchymal stromal cell minimal quality requirements for clinical application. In: Stem Cells and Development. 2015 ; Vol. 24, No. 6. pp. 677-685.
@article{e99c098cf1d94adda806cf37dc65f109,
title = "Ex vivo expanded mesenchymal stromal cell minimal quality requirements for clinical application",
abstract = "Mesenchymal stromal cells (MSCs), as advanced therapy products, must satisfy all the requirements for human use of medicinal products, aiming to maintain the quality and safety of the cells. The MSC manufacturing process for clinical use should comply with the principles of Good Manufacturing Practice (GMP). This ensures that cell preparations are produced and controlled, from the collection and manipulation of raw materials, through the processing of intermediate products, to the quality controls, storage, labeling and packaging, and release. The objective of this document is to provide the minimal quality requirements for the MSC production and its delivery for clinical use, so that the safety of the final cell therapy product will not be compromised. For this purpose, the document evaluates the most important steps of GMP-compliant MSC production: the isolation and expansion process; the validation phase of the process, including all quality controls for the characterization, functionality, potency, and safety of MSCs; and the quality control at the batch release to guarantee the safety of patient infusion.",
author = "Torre, {Maria Luisa} and Enrico Lucarelli and Simona Guidi and Maura Ferrari and Giulio Alessandri and {De Girolamo}, Laura and Augusto Pessina and Ivana Ferrero",
year = "2015",
month = "3",
day = "15",
doi = "10.1089/scd.2014.0299",
language = "English",
volume = "24",
pages = "677--685",
journal = "Stem Cells and Development",
issn = "1547-3287",
publisher = "Mary Ann Liebert Inc.",
number = "6",

}

TY - JOUR

T1 - Ex vivo expanded mesenchymal stromal cell minimal quality requirements for clinical application

AU - Torre, Maria Luisa

AU - Lucarelli, Enrico

AU - Guidi, Simona

AU - Ferrari, Maura

AU - Alessandri, Giulio

AU - De Girolamo, Laura

AU - Pessina, Augusto

AU - Ferrero, Ivana

PY - 2015/3/15

Y1 - 2015/3/15

N2 - Mesenchymal stromal cells (MSCs), as advanced therapy products, must satisfy all the requirements for human use of medicinal products, aiming to maintain the quality and safety of the cells. The MSC manufacturing process for clinical use should comply with the principles of Good Manufacturing Practice (GMP). This ensures that cell preparations are produced and controlled, from the collection and manipulation of raw materials, through the processing of intermediate products, to the quality controls, storage, labeling and packaging, and release. The objective of this document is to provide the minimal quality requirements for the MSC production and its delivery for clinical use, so that the safety of the final cell therapy product will not be compromised. For this purpose, the document evaluates the most important steps of GMP-compliant MSC production: the isolation and expansion process; the validation phase of the process, including all quality controls for the characterization, functionality, potency, and safety of MSCs; and the quality control at the batch release to guarantee the safety of patient infusion.

AB - Mesenchymal stromal cells (MSCs), as advanced therapy products, must satisfy all the requirements for human use of medicinal products, aiming to maintain the quality and safety of the cells. The MSC manufacturing process for clinical use should comply with the principles of Good Manufacturing Practice (GMP). This ensures that cell preparations are produced and controlled, from the collection and manipulation of raw materials, through the processing of intermediate products, to the quality controls, storage, labeling and packaging, and release. The objective of this document is to provide the minimal quality requirements for the MSC production and its delivery for clinical use, so that the safety of the final cell therapy product will not be compromised. For this purpose, the document evaluates the most important steps of GMP-compliant MSC production: the isolation and expansion process; the validation phase of the process, including all quality controls for the characterization, functionality, potency, and safety of MSCs; and the quality control at the batch release to guarantee the safety of patient infusion.

UR - http://www.scopus.com/inward/record.url?scp=84924366186&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924366186&partnerID=8YFLogxK

U2 - 10.1089/scd.2014.0299

DO - 10.1089/scd.2014.0299

M3 - Article

C2 - 25517941

AN - SCOPUS:84924366186

VL - 24

SP - 677

EP - 685

JO - Stem Cells and Development

JF - Stem Cells and Development

SN - 1547-3287

IS - 6

ER -